

ERBB2 Conjugated Antibody

Catalog No: #C43832



Package Size: #C43832-AF350 100ul #C43832-AF405 100ul #C43832-AF488 100ul
 #C43832-AF555 100ul #C43832-AF594 100ul #C43832-AF647 100ul
 #C43832-AF680 100ul #C43832-AF750 100ul #C43832-Biotin 100ul

Orders: order@signalwayantibody.com
 Support: tech@signalwayantibody.com

Description

Product Name	ERBB2 Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous levels of total ERBB2 protein.
Immunogen Description	Synthetic peptide of human ERBB2
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	NEU;NGL;HER2;TKR1;CD340;HER-2;MLN19;HER-2/neu
Accession No.	Swiss-Prot#:P04626NCBI Gene ID:2064NCBI mRNA#:NCBI Protein#:NP_004439
Uniprot	P04626
GeneID	2064;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	138
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members. Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway.

Note: This product is for in vitro research use only